Geneyx

Geneyx is a privately held biotechnology company specializing in artificial intelligence-driven genomic data analysis and interpretation, particularly for rare and hereditary diseases. Their Geneyx Analysis platform supports clinical and research use of next-generation sequencing (NGS) data, offering secondary analysis (from FASTQ to VCF), clinical interpretation, and pharmacogenomics updates aligned with CPIC and PharmGKB for 87 genes and 321+ drugs. Geneyx also partners with Ocean Genomics to offer SVDuo™, an innovative software for integrated DNA and RNA analysis, enhancing structural variant detection for disease diagnosis and personalized medicine.

Geneyx’s platform is used by hospitals, commercial laboratories, and researchers to improve diagnostic yield, risk prediction, and clinical decision-making, supporting the development of targeted and personalized therapeutics. The company has raised $10 million in funding and is based in Wilmington, Delaware, with roots in Israel. Notable investors include Accenture Ventures, and the company is recognized for its advanced AI-driven, multi-omics data analysis capabilities.